TALLAHASSEE, Fla—Attorney General Pam Bondi’s Office announced that Florida joined 28 other states and the federal government to settle allegations that Celgene Corporation, a biopharmaceutical company, engaged in a variety of marketing schemes to promote the off-label use of two drugs, Thalomid® and Revlimid®. The company also allegedly promoted the drugs by paying kickbacks to providers in order to induce the providers to prescribe the drugs.
As part of the settlement, Celgene will pay the states and the federal government $280 million, of which more than $20 million will go to state Medicaid programs. The payment to the Medicaid programs will resolve civil allegations that the company unlawfully marketed the two drugs, causing false claims to be submitted to government health care programs. Florida will receive more than $1.4 million as part of the settlement.
The settlement stems from a whistleblower lawsuit, U.S., et al, ex. rel. Beverly Brown v Celgene Corporation, Civ. Action No. CV10-03165, filed in the United States District Court for the Central District of California.
To view a copy of the settlement, click here.